By Ed Miseta, Editor-in-Chief, Clinical HeadFollow me on Twitter @EdClinical
Karen Correa
Karen Correa’s work in the clinical area began in 1993 as coordinator of clinical studies studies. Since then, she has worked at CRO giants, small biotechs and pharmaceutical giants, and in 2020 accepted the position of Vice President, Head of Global Clinical Operations for Takeda.
Correa has been empowered to seek out And Takeda as the most productive spouse for his patients, sites and CROs. “Across the industry, we hear a lot about being a ‘sponsor of choice,'” he explains. that this effort was original and not just for the program, I sought to make sure that meant making a real difference for all of our spouses.
A NEW OPTIMIZATION TEAM
From the beginning, Correa has created an exam optimization team to identify demanding verification situations and propose pragmatic course correction solutions. For example, the team knew that patient diversity is an issue. To mitigate this problem, they hired a Director of Diversity, Equity and Inclusion ( Delaware
While Takeda already focuses on diversity, the company believes innovations can only be made to better inform workers about what ED looks like.
The optimization team combines the feasibility, commissioning and DE groups
INCREASE THE IMPACT OF PREDICTABLE DELIVERIES
One of the goals of this new team is to look for what Correa calls predictable delivery. Whether it’s Takeda, research sites, or CRO, she believes that all stakeholders involved in a clinical trial can deliver faster, better, and more efficiently. This starts with making the delivery of clinical trial activities more predictable.
When talking about delivery, many sponsors tend to attach great importance to CROs. Correa agrees that it is vital that CRO partners deliver results within the agreed deadlines. Data from their CROs, identified an opportunity to refine their own data, insights, and site relationships to optimize exam execution. “
The newly formed exam optimization team will conduct its own independent assessment of the expected test functionality and work with CRO partners to arrive at ambitious but achievable exam designs. Meetings are held with the CRO and partners to monitor progress and timelines.
FEEDBACK LOOPS ARE VITAL
When Takeda embarked on this new strategic journey, Correa admits they knew they knew their partners’ wishes. However, the company sought to perceive those desires rather than relying on assumptions. To perceive those desires, Americans would want to pay attention to the groups’ comments. .
Takeda has established comment loops with sites and CROs. A control team in the healing domain is guilty of achieving ongoing interactions with those partners. While the goal of those communications is to keep testing activities going, Takeda also uses those opportunities to discover it operates as an organization.
The new comment loops had many aspects, such as surveys. These surveys provided the company with insights into how to execute strategies and where help was needed.
“During the COVID pandemic, we learned that sites were incredibly overloaded,” Correa says. “The pandemic has challenged sites in terms of time, resources, ability to conduct trials, and even patient access. , we let them know that we were empathetic to this scenario and that we were in a position to help them. “
In some cases, the company responded to suggestions by offering more resources and support. In others, this involved taking a closer look at exam protocols. The groups reviewed those protocols to see if they could be simplified or simplified. COVID also accelerated. Takeda to fully adopt a decentralized technique for trials, a clinical style that the company already socializes, to see what other activities can be moved outside of clinics. The company is recently conducting this protocol assessment at the beginning of a trial.
ACTING ON PATIENTS’ PERSPECTIVES
Historically, Takeda’s Office of Patient Engagement collected feedback by conducting concentrated teams with patients prior to trials. Feedback on their experiences, what works, and what could be improved is collected from patients, as well as from patient counseling forums and patient advocacy teams. Correa notes that Takeda needs to use this data for the overall patient experience.
“We’re in those comments and wondering if there’s a way to replace a protocol or if we can put something new, like a wireless device, in place that can reduce the burden of clinical trial participation for patients. Patient data is shared with other teams to see how and where innovations can be made at each level of the test journey.
Another effort is to make sure Takeda deepens his understanding of the patient’s adventure and impact on the research site. This effort will involve soliciting input from other site staff members, such as exam coordinators and pharmacists, as well as principal investigators (PI). These Americans can provide useful information about difficult situations and study pitfalls that PIs may not be aware of.
SERVICE PROVIDER COMMENTS
While patient and site feedback is important, Takeda also sought to get information from its CRO partners, as they have a wealth of experience through their work with multiple sponsors. A clinical partner management office within Takeda is guilty of overseeing the relationship with CROs. . A Takeda partnership manager is assigned to each CRO partner. These Americans bring to the field to oversee the suitability of society a myriad of metrics and kpis. They also collaborate with the clinical operations team to influence plan development and execution. Purpose – Targeted meetings ensure that Takeda oversees delivery at the point of analysis and functional and ensures strategic alignment at the executive point.
Meetings are held regularly on a monthly and quarterly basis and are structured in such a way as to facilitate discussion about the building relationships and those necessary to deal with demanding trial situations. Suggestions are presented through both sides with an active discussion on merits and investments. Sometimes, meetings will allow Americans to get to know each other. Correa says some meetings will only solicit feedback from CROs on what Takeda could improve. build an open relationship,” Correa says.
GOOD PLANNING IS NEEDED
With any well-defined activity, it takes a smart dose of plan-making to kick-start the effort. Once concepts and suggestions from the feedback loops began to arrive, the elaboration of plans for the implementation of new activities is carried out through multifunctional groups. groups collaborated with express objectives that emerged from the comments.
“We seek to involve everyone,” says Correa. We come with all the functional spaces in the monthly classes learned and the most productive practices ed in all stages of execution, from the beginning of the exam to the blocking of the database. This includes, but is not limited to, learned monetary classes and quality. These sessions allow groups to use feedback and our efforts in the spaces they want to improve. »
The promotion of replacement control was mandatory to enforce many of these new comment loops. Today, Correa points out that this is something that frequently happens with the help of the quick playbooks that have been developed. Correa describes those playbooks as a key resource describing Takeda’s strategy and vision, structure and key activities.
A playbook was developed for Correa’s global clinical operations group. Another was developed to announce diversity in clinical trials. Strategy manuals are provided to new workers to facilitate their incorporation. Correa believes that the right education and incorporation, especially when a vision is obviously explained with groups and partners, relationships of will.
A POSITIVE COVID RESULT
While the COVID-19 pandemic has had a negative effect on clinical trials, patients, and sites, Correa notes that it has helped drive the use of knowledge and virtual equipment in the industry, adding corporations that are taking a closer look at a decentralized technique. to clinical trials. ” Data are paramount in clinical trials,” Correa says. “Decentralized trials allow us to gather insights into new and advanced tactics while gathering the wishes of sites and patients. “
The pandemic has replaced the way Takeda approaches plan-making and testing. Even when the pandemic is over, the company’s purpose is never to experience the outdated way again.
Receive Life Science Leader articles in your inbox.